Recurrent Uterine Corpus Sarcoma Clinical Trial
Official title:
A Phase II Evaluation of Thalidomide (NSC #66847) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Phase II trial to study the effectiveness of thalidomide in treating patients who have recurrent or persistent cancer of the uterus. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
PRIMARY OBJECTIVES:
I. Determine the antitumor cytostatic activity of thalidomide, as measured by the probability
of progression-free survival (PFS) for at least 6 months, in patients with recurrent or
persistent uterine leiomyosarcoma.
II. Determine the nature and degree of the toxicity of this drug in these patients.
III. Determine the partial and complete response rates in patients treated with this drug.
IV. Determine the duration of PFS and overall survival of patients treated with this drug.
V. Determine the effect of this drug on initial performance status in these patients.
VI. Determine the effects of this drug at 4 weeks on endogenous angiogenesis factors
(vascular endothelial growth factor and basic fibroblast growth factor) in plasma and urine
of these patients.
VII. Assess the association of endogenous angiogenesis factors with clinical outcome (PFS) in
patients treated with this drug.
OUTLINE: This is a multicenter study.
Patients receive oral thalidomide once daily on days 1-28. Courses repeat every 4 weeks in
the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then
annually thereafter.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01168232 -
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
|
Phase 2 | |
| Completed |
NCT00025506 -
Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
|
Phase 2 | |
| Completed |
NCT01220609 -
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
|
Phase 2 | |
| Terminated |
NCT01012297 -
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma
|
Phase 3 | |
| Completed |
NCT01548482 -
Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
|
Phase 1 | |
| Completed |
NCT00114218 -
Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer
|
Phase 2 | |
| Completed |
NCT01154452 -
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
|
Phase 1/Phase 2 | |
| Completed |
NCT01098630 -
Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer
|
||
| Completed |
NCT01247571 -
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
|
Phase 2 | |
| Completed |
NCT00031629 -
Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus
|
Phase 2 | |
| Completed |
NCT01637961 -
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
|
Phase 2 |